Figure 3
-Histology slides confirming the diagnosis of malignant melanoma. a) Small bowel mucosa (black arrow) with submucosal infiltration by solid epithelioid tumour with cytonuclear atypia (white arrow) (28.6×, hematoxylin and eosin and periodic acid Schiff ). b) Cytoplasmic positivity of the tumour cells (arrow) for Melan-A protein (123.6× immunohistochemistry).
Source publication
Malignant melanoma is commonly known for its high probability of metastasizing to distant organs. Metastases to gastrointestinal tract are well documented, but resulting jaundice is only scarcely seen. We present a case of histologically verified metastasis of amelanotic melanoma to the head of pancreas infiltrating the common bile duct and consequ...
Context in source publication
Context 1
... histopathology findings confirmed intestinal tissue with an infiltration by amelanotic malignant melanoma metastatic cells. The immunohistochemical stains for melanoma specific markers S-100 protein, SOX10, and Melan A were all positive and therefore confirmed the diagnosis of malignant melanoma ( Figure 3). The bioptic tissue was also analysed for mutations in BRAF genes which could guide further targeted treatment. ...
Similar publications
Most intraocular metastatic tumors occur in the uveal tract, while isolated metastasis to the optic nerve is rarely found. Breast and lung cancers are the tumor types metastasizing to the eye most frequently; however, metastases of prostate cancer, melanoma, gastrointestinal tract, and renal tumors have also been reported. We describe three rare ca...
Citations
Melanoma is a malignant tumor that originates from melanocytes, most of which are of cutaneous origin. Most melanomas identified in the pancreas are metastatic, and primary pancreatic melanoma is extremely rare and has rarely been discussed. The correct preoperative diagnosis of pancreatic metastatic melanoma, especially primary melanoma, is challenging. Herein, we report a 43-year-old man who presented to our hospital due to unexplained left abdominal distension and pain. Abdominal ultrasound examination demonstrated multiple space-occupying lesions of the pancreas, and hypoechoic masses partially filled the splenic vein behind the pancreatic body. In the contrast-enhanced ultrasound (CEUS), all of these lesions showed iso-enhancement to slight hypo-enhancement in the arterial phase and hypo-enhancement in the venous phase. Masses in the splenic vein also showed hypo-enhancement. Imaging features suggested that the pancreatic lesions were malignant tumors. The tumor markers carcinoembryonic antigen, carbohydrate antigen 125 and carbohydrate antigen 19-9 were within normal limits. Based on clinical symptoms, imaging findings and incidence of pancreatic tumors, the patient’s clinical diagnosis was pancreatic carcinoma. Surgery was performed for the patient, while postoperative pathology confirmed malignant melanoma of the pancreas. Therefore, it is significant to identify the clinical and imaging manifestations of pancreatic melanoma in order to better manage the disease. Herein, we reported this case and reviewed the literature from 2000 to 2021 on the clinical and imaging features of 26 patients with pancreatic melanoma. It may improve clinicians’ awareness of the clinical and imaging performance of pancreatic melanoma, resulting in improved diagnosis, differential diagnosis, treatment, and outcomes.
Isolated pancreatic metastases from melanoma are rare with high mortality rate and account for less than 1% of metastatic melanomas. Treatment options are limited with highest overall survival reported in those with complete surgical resection. Of cases reported in the literature with nonsurgical management, highest length of survival was reported to be 10 months. We report a case of malignant melanoma with isolated pancreatic metastasis treated with interferon therapy and immunotherapy, with evidence of progressive tumor shrinkage and survival at 38 months.
